IPP Bureau
Morepen Laboratories appoints Amrit Ravi as Vice President
By IPP Bureau - October 01, 2024
He holds a Master’s in Management from the National University of Singapore
Krsnaa Diagnostics and Medikabazaar to invest Rs. 300+ crore to set up imaging centers
By IPP Bureau - October 01, 2024
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
USFDA completes inspection at Biocon Biologics’ Insulins facility at Malaysia
By IPP Bureau - September 30, 2024
The inspection concluded with the issuance of a form 483 with five observations
USFDA inspection update on Jubilant HollisterStier’s Montreal facility
By IPP Bureau - September 30, 2024
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Dr. Reddy's invests US$ 620 million in Switzerland subsidiary
By IPP Bureau - September 30, 2024
Briefs: Lupin, Alembic Pharmaceuticals and Piramal Pharma
By IPP Bureau - September 29, 2024
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Bayer submits supplemental new drug application to USFDA seeking expanded indication for NUBEQA
By IPP Bureau - September 29, 2024
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Amcor's long-term SBTi targets confirmed
By IPP Bureau - September 28, 2024
The net-zero target approval complements the company's near-term emission reduction targets
Lupin signs distribution agreement with Celnova for orphan drug NaMuscla
By IPP Bureau - September 28, 2024
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
AbbVie submits Biologics license application to USFDA for Telisotuzumab Vedotin
By IPP Bureau - September 28, 2024
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
FDA approves Bristol Myers Squibb’s Cobenfy
By IPP Bureau - September 28, 2024
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Baxter launches nextgen airway clearance system
By IPP Bureau - September 28, 2024
Developed in consultation with clinicians and patients for an enhanced user experience
Zydus receives USFDA final approval for Enzalutamide Capsules, 40 mg
By IPP Bureau - September 28, 2024
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
AIIA starts “Ayurveda innovation for Global Health” campaign
By IPP Bureau - September 28, 2024
Potential of Ayurveda’s contribution in global health system through various innovative practices
